Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

141.00 -2.06 (-1.44%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
49 50 Next >
Biogen To Report Q3 Earnings: Here's What To Expect
Biogen will report third-quarter 2022 results on Oct 25, before market open. 
Via Talk Markets
3 Alzheimer's Therapy Stocks to Invest in
Alzheimer's treatments could make a big winner of these stocks. 
Via The Motley Fool
This Beaten-Down ETF Is Still a Screaming Bear-Market Buy
Investors wanting to profit from a potential biotech sector bounce should love this exchange-traded fund. 
Via The Motley Fool
Biogen Whale Trades For October 20
A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 12 strange trades. 
Via Benzinga
Where Will Biogen Be in 5 Years?
Is this biotech an investment worth buying and holding today? 
Via The Motley Fool
Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients
Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which... 
Via FinancialNewsMedia
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Biogen's Stock Pullback Offers a Second Chance
Biogen is positioned to become more diversified over time. A diminishing risk profile combined with emerging growth prospects make the stock attractive. 
Via MarketBeat
Exposures Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
FDA Pushes Extends Review For Biogen's Amyotrophic Lateral Sclerosis Drug
Via Benzinga
Sage Therapeutics/Biogen Highlight Additional Data From Depression Candidate
Via Benzinga
Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen
From Biogen Inc.
Via GlobeNewswire
This Is What Whales Are Betting On Biogen
Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts
Stifel upgraded Biogen Inc (NASDAQ: BIIB) from Hold to Buy, saying shares have faded since positive lecanemab data in mild Alzheimer's. 
Via Benzinga
Biogen Soars On Upgrade; Why Lilly, Roche Won't Block Its Alzheimer's Opportunity
Even a percentage of the Alzheimer's market could mean $7 billion for Biogen. 
Via Investor's Business Daily
GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY®
From GoodRx
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
Upgrades 
Via Benzinga
Elliott Wave Technical Analysis: Biogen, Inc. - Thursday, Oct. 13
Biogen Inc. is moving as predicted, looking for this pullback to this support as we have had a huge gap to the upside. 
Via Talk Markets
Is Seagen Stock a Buy Now?
It's growing faster than competitors, but headwinds might soon bog it down. 
Via The Motley Fool
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients
Via Benzinga
Does Biogen's Recent Win Make It a Must-Buy Stock?
Will Biogen investors be let down again, or is this the real deal? 
Via The Motley Fool
4 Biotech Stocks With Huge Incoming Catalysts
All four of these drugmakers are expecting important FDA approval decisions over the next few months. 
Via The Motley Fool
Biotech Stocks Well-Positioned For The Fourth Quarter
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far. 
Via Talk Markets
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
Via Benzinga
These 7 Biotech Stocks Are Set to Boom in 2023
This article looks at seven biotech stocks that look like good options to move significantly higher in 2023 
Via InvestorPlace
Eli Lilly Leads 5 Stocks To Watch In Bear Market
Eli Lilly is holding up, while others crumbled Friday amid the market sell-off. 
Via Investor's Business Daily
MarketBeat: Week in Review 10/3-10/7
The jobs report is fueling a sell-off to end the week with more volatility on tap for next week. Here are some of the most popular articles from this week. 
Via MarketBeat
Topics Economy Electric Vehicles
Exposures Electric Vehicles Interest Rates
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2022
Upgrades 
Via Benzinga
One Of Eli Lilly's Most Anticipated Drugs Could Hit The Market Next Year
The Street is closely watching Lilly's efforts in obesity and Alzheimer's. 
Via Investor's Business Daily
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.